ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0198

A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis

Kaleb Michaud1, Jennifer Merickel1, Yeongjin Gwon1, Harlan Sayles1, Haley Kampschnieder1, Rebecca Hiebert1, Alison Petro1, Bryant England1, Matthew Rizzo1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2020

Keywords: Disease Activity, quality of life, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Automobile driving is an instrumental activity of daily living. Owing to symptoms and functional impairment, patients with rheumatoid arthritis (RA) rely disproportionately on driving for the preservation of health, well-being, and quality of life1. To date, there have been no rigorously designed prospective studies examining driving performance in patients with RA.  This prospective cohort study compared variability in longitudinal (acceleration/braking) and lateral (steering) vehicle acceleration as measures of vehicle control between drivers with RA and healthy controls (HC).

Methods: Patients with RA were recruited from an academic rheumatology practice and were required to have at least one swollen joint and a CDAI score ≥6 to participate.  HCs were recruited using advertisements and a pool of local study volunteers. Data collection occurred over 2, 4-week periods (separated by 2 months) of continuous naturalistic driving observation. Driving data were collected using instrumentation installed in participants’ own vehicles, collecting video, audio, GPS, speed, acceleration and engine data. Data were aggregated into 45-second segments (from start-to-end) of uninterrupted driving. Segments with >20 seconds of missing data or mean speeds < 5 mph were excluded. Associations of disease status (RA vs. HC) and disease activity (CDAI score, RA only) with acceleration variability (standard deviations, SDs) were examined using mixed-effect linear regression models, accounting for between-patient variability.

Results: Characteristics of RA and HC subjects are shown in Table 1. There were 232,538 driving segments (2,906 driving hours) analyzed. Factors associated with variability in longitudinal and lateral acceleration included RA disease status, higher disease activity in RA, study period, season, and mean vehicle speed (Table 2, Figure 1). Increases in disease activity between periods 1 and 2 tended to produce more erratic braking/accelerating (increased longitudinal variability; estimate = 0.0004; p = 0.05) without affecting steering.

Conclusion: To our knowledge, this is the first study quantifying naturalistic driving in the real world in patients with RA. These results link RA and heighted arthritis disease activity with aberrant vehicle control. Specifically, increased RA disease activity reduces steering variability while simultaneously increasing erratic/harsh braking and accelerating. These findings support the need for further research to map these observed patterns in vehicle control to metrics of driver risk, and, in turn, to link patterns of real world driving behavior to diagnosis and disease activity.

1. Vrkljan BH et al. Supporting safe driving with arthritis: developing a driving toolkit for clinical practice and consumer use. Am J Occup Ther. 2010;64(2):259-67.

*HAQ-II = Health Assessment Questionnaire-II; CDAI = Clinical Disease Activity Index

*Significant associations shown in bold; CDAI = Clinical Disease Activity Index; RA = rheumatoid arthritis; HC = healthy controls; mph = miles per hour

Figure 1: Plot of variability in lateral (left panel) and longitudinal (right panel) acceleration by vehicle speed


Disclosure: K. Michaud, Rheumatology Research Foundation, 2; J. Merickel, None; Y. Gwon, None; H. Sayles, None; H. Kampschnieder, None; R. Hiebert, None; A. Petro, None; B. England, None; M. Rizzo, None; T. Mikuls, Horizon Therapeutics, 2.

To cite this abstract in AMA style:

Michaud K, Merickel J, Gwon Y, Sayles H, Kampschnieder H, Hiebert R, Petro A, England B, Rizzo M, Mikuls T. A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-prospective-cohort-study-of-vehicle-control-as-a-measure-of-driving-performance-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-prospective-cohort-study-of-vehicle-control-as-a-measure-of-driving-performance-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology